Cumberland Pharmaceuticals (NASDAQ: CPIX) shares Q3 and nine-month update

Rhea-AI Filing Summary

Cumberland Pharmaceuticals Inc. filed a current report to furnish a press release dated November 4, 2025. The press release provides a company update and the financial results for the three and nine months ended September 30, 2025. The information is furnished under Item 2.02 regarding results of operations and financial condition and is not deemed filed for liability purposes under Section 18 of the Exchange Act unless later specifically incorporated by reference.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001087294false00010872942025-11-042025-11-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

November 4, 2025 (November 4, 2025)

Date of Report (date of earliest event reported)

CUMBERLAND PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

Tennessee			001-33637						62-1765329
(State or other jurisdiction of incorporation or organization)			(Commission File Number)						(I.R.S. Employer Identification No.)

1600 West End Avenue, Suite 1300 Nashville, Tennessee 37203

(Address of Principal Executive Offices)

(615) 255-0068

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, no par value			CPIX			NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02     Results of Operations and Financial Condition.

On November 4, 2025, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release which provided a company update and the financial results for the three and nine months ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02.

This information is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless specifically incorporated by reference in a document filed under the Securities Act of 1933, as amended, or the Exchange Act. By filing this report on Form 8-K and furnishing this information, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by Item 2.02.

Item 9.01    Financial Statements and Exhibits

    (d) Exhibits

Exhibit No.						Description
99.1						Press release dated November 4, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cumberland Pharmaceuticals Inc.

Dated: November 4, 2025

By:

/s/ John Hamm

John Hamm

Chief Financial Officer

FAQ

What did Cumberland Pharmaceuticals (CPIX) disclose in this 8-K filing?

The company furnished a press release dated November 4, 2025 that provides a company update and financial results for the three and nine months ended September 30, 2025.

Which period do Cumberland Pharmaceuticals' latest results in this filing cover?

The press release attached to the filing reports financial results for the three and nine months ended September 30, 2025.

Under which item did Cumberland Pharmaceuticals (CPIX) furnish the press release?

The press release was furnished under Item 2.02, Results of Operations and Financial Condition.

Is the information in Cumberland Pharmaceuticals' 8-K considered filed with the SEC?

The information is furnished and is not deemed filed for purposes of Section 18 of the Exchange Act unless it is specifically incorporated by reference in a Securities Act or Exchange Act filing.

What exhibit is included with Cumberland Pharmaceuticals' November 4, 2025 8-K?

The filing includes Exhibit 99.1, which is the press release dated November 4, 2025.

Who signed the Cumberland Pharmaceuticals (CPIX) 8-K related to the November 4, 2025 press release?

The report was signed on behalf of Cumberland Pharmaceuticals Inc. by John Hamm, Chief Financial Officer.